Not a good buy right now: the stock is in a confirmed downtrend (bearish MAs + weakening MACD), and there are no Intellectia buy signals to override the technical weakness.
Oversold (RSI_6 ~15) can produce a short bounce, but with momentum still deteriorating, the odds favor further weakness near-term.
For an impatient investor unwilling to wait for confirmation, the risk/reward is unfavorable at current levels; best stance is to avoid new entries until trend/momentum improves.
Technical Analysis
Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating persistent downside pressure across long-, mid-, and short-term timeframes.
Momentum: MACD histogram is negative (-0.0637) and expanding lower, suggesting downside momentum is strengthening rather than stabilizing.
Overbought/oversold: RSI_6 at ~15 is deeply oversold, which can trigger reflex rallies, but oversold alone is not a reversal signal.
Key levels: Current price ~2.83 is below Pivot 3.416 and below S1 2.931; next meaningful support is S2 2.631. Resistance levels to reclaim: 2.93 (S1) then 3.42 (Pivot).
Pattern-based forward odds (provided): 60% chance of -0.25% next day, -1.76% next week, -4.74% next month → bearish bias remains.
Partnership catalyst: Aclarion partnered with Source Healthcare (Los Angeles) to expand availability of Nociscan for chronic low back pain treatment, which could support adoption/revenue visibility.
Technical mean-reversion setup: extremely oversold RSI can attract short-term dip buyers if broader selling pressure eases.
Hedge funds/insiders: neutral trend signals (no notable recent accumulation or distribution) reduce the risk of a fresh bearish “smart money” wave—though it also means no clear sponsorship.
Neutral/Negative Catalysts
and well under Pivot (3.
keeps the chart structurally weak; next support sits lower at 2.
Near-term statistical bias (provided) points to continued declines over 1-week and 1-month horizons.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 18,942, up 31.48% YoY (growth off a very small base).
Net income: -1,706,294 (loss), improved 23.80% YoY (loss narrowing), but still meaningfully negative.
EPS: -2.93, down 99.78% YoY (material deterioration in per-share results despite the net loss improving—suggests share count/other per-share dynamics working against shareholders).
Gross margin: 23.15, down 148.16% YoY (sharp margin compression is a major fundamental negative).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so recent Wall Street upgrades/downgrades and target revisions cannot be confirmed.
Practical “pros vs cons” view based on available info: Pros = revenue growth and a commercial partnership that could support adoption; Cons = ongoing losses, severe margin deterioration, and a technically weak chart with no supportive trading signals.
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23 USD with a low forecast of 23 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23 USD with a low forecast of 23 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
